4563. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia.
作者: Pau Montesinos.;Christian Recher.;Susana Vives.;Ewa Zarzycka.;Jianxiang Wang.;Giambattista Bertani.;Michael Heuser.;Rodrigo T Calado.;Andre C Schuh.;Su-Peng Yeh.;Scott R Daigle.;Jianan Hui.;Shuchi S Pandya.;Diego A Gianolio.;Stephane de Botton.;Hartmut Döhner.
来源: N Engl J Med. 2022年386卷16期1519-1531页
The combination of ivosidenib - an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) - and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia.
4564. Calorie Restriction with or without Time-Restricted Eating in Weight Loss.
作者: Deying Liu.;Yan Huang.;Chensihan Huang.;Shunyu Yang.;Xueyun Wei.;Peizhen Zhang.;Dan Guo.;Jiayang Lin.;Bingyan Xu.;Changwei Li.;Hua He.;Jiang He.;Shiqun Liu.;Linna Shi.;Yaoming Xue.;Huijie Zhang.
来源: N Engl J Med. 2022年386卷16期1495-1504页
The long-term efficacy and safety of time-restricted eating for weight loss are not clear.
4565. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
作者: Myron J Levin.;Andrew Ustianowski.;Stéphane De Wit.;Odile Launay.;Miles Avila.;Alison Templeton.;Yuan Yuan.;Seth Seegobin.;Adam Ellery.;Dennis J Levinson.;Philip Ambery.;Rosalinda H Arends.;Rohini Beavon.;Kanika Dey.;Pedro Garbes.;Elizabeth J Kelly.;Gavin C K W Koh.;Karen A Near.;Kelly W Padilla.;Konstantina Psachoulia.;Audrey Sharbaugh.;Katie Streicher.;Menelas N Pangalos.;Mark T Esser.; .
来源: N Engl J Med. 2022年386卷23期2188-2200页
The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days.
|